Moody’s revises Pfizer to stable

Moody's Investors Service said it affirmed the ratings of Pfizer Inc. and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating.

The outlook was revised to stable from negative. This action follows the announcement that Pfizer will not pursue a split of its pharmaceutical business.

"Pfizer's decision to keep the business whole removes a key overhang to the credit profile because a split had credit negative implications," Moody's senior vice president Michael Levesque said in a news release.

"The stable rating outlook reflects Pfizer's solid earnings trends for the next several years, and long-term growth opportunities from the acquisitions of Medivation and Anacor."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.